79 results
DEFA14A
KROS
Keros Therapeutics Inc
17 Apr 24
Additional proxy soliciting materials
4:05pm
Meeting of Stockholders; Nominees: 01 Jasbir Seehra, Ph.D. 02 Nima Farzan 03 Julius Knowles 2. To ratify the selection by the Audit Committee
424B5
KROS
Keros Therapeutics Inc
4 Jan 24
Prospectus supplement for primary offering
4:02pm
companies and from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm
424B5
KROS
Keros Therapeutics Inc
3 Jan 24
Prospectus supplement for primary offering
4:04pm
mandatory audit firm rotation.
We may take advantage of these exemptions until December 31, 2025 or such earlier time that we are no longer an emerging
8-K
7byras
6 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
DEFA14A
sj590uipblk07ypyrdh
24 Apr 23
Additional proxy soliciting materials
4:02pm
8-K
ckja3d
19 Apr 23
Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
8:01am
424B5
gnjm2njnnxhuu17l4
12 Dec 22
Prospectus supplement for primary offering
4:02pm